NORTH AMERICAN VACCINE's ACELLULAR PERTUSSIS COMPONENT IS 71% EFFECTIVE
NORTH AMERICAN VACCINE's ACELLULAR PERTUSSIS COMPONENT IS 71% EFFECTIVE against whooping cough in infants, according to a National Institute of Child Health & Human Development-sponsored Phase III randomized, double-blind placebo controlled trial, the institute announced Nov. 22. Conducted at the University of Goteborg in Sweden by co-principal investigators John Taranger and Birger Trollfors, the three-year trial tested the North American Vaccine-manufactured acellular pertussis vaccine (consisting solely of a detoxified pertussis toxin), which the company compounded as DTaP using diphtheria and tetanus toxoids manufactured by the Statens Semminstitut, Copenhagen.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth